肺がん治療の世界市場

肺がん治療の世界市場は2030年までに791億米ドルに到達

2024年に509億米ドルと推定される肺がん治療の世界市場は、分析期間2024-2030年にCAGR 7.6%で成長し、2030年には791億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるNSCLCがん治療は、CAGR 6.2%を記録し、分析期間終了時には462億米ドルに達すると予測されます。SCLCがん治療セグメントの成長率は、分析期間中CAGR 9.9%と推定されます。

米国市場は139億米ドルと推定、中国はCAGR 11.7%で成長すると予測

米国の肺がん治療市場は2024年に139億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに166億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.9%と7.3%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の肺がん治療市場- 主要動向と促進要因まとめ

なぜ肺がんは世界のオンコロジー技術革新の中心であり続けるのか？

肺がんは、世界のがん関連死亡者数の最多を占め、世界の腫瘍学における最も手ごわい課題の一つであり続けています。主に非小細胞肺がん（NSCLC）と小細胞肺がん（SCLC）に分類されるこの病気は、しばしば進行した段階で診断されるため、予後不良で治療の緊急性が高いです。化学療法と放射線療法に依存してきた歴史は、現在、治療パラダイムを変革しつつある、より個別化された、標的を絞った、免疫に基づくアプローチに道を譲りつつあります。分子診断、バイオマーカー探索、精密治療における革新は、臨床医が遺伝子変異、組織学的サブタイプ、免疫プロファイルに基づいて治療法を調整することを可能にしています。

生存予後を改善することが急務であるため、免疫療法、標的キナーゼ阻害剤、無増悪生存期間と全生存期間に漸進的ではあるが有意な改善をもたらす併用レジメンの導入が加速しています。リキッドバイオプシーツール、次世代シークエンシング（NGS）、コンパニオン診断薬は、がん専門医がかつてない精度で患者を適切な治療法に適合させるのに役立っています。これらの開発は、複雑でコストがかかるもの、肺がんを一様に厳しい診断から、バイオマーカーで定義された層別化された一連の病態と多様な治療経路へと徐々に変化させつつあります。

標的療法と免疫療法は臨床をどのように変えているのか？

肺がん治療における最も革新的な変化の一つは、EGFR、ALK、ROS1、BRAF、METなどの実用的な変異を有する患者に対する標的治療の拡大です。オシメルチニブ、クリゾチニブ、エントレクチニブなどのこれらの治療薬は、腫瘍の増殖を促す異常なシグナル伝達経路を遮断します。オイメルチニブ、クリゾチニブ、エントレクチニブなどのこれらの治療薬は、腫瘍増殖を促進する異常なシグナル伝達経路を遮断します。これらの治療薬の採用により、細胞毒性化学療法を受けなければならなかった患者の生存期間が延長し、QOLが改善しました。さらに、EGFR陽性腫瘍におけるT790Mのような耐性変異は、治療の複雑化と個別化を反映し、現在、第2世代および第3世代の阻害剤で対処されています。

ペムブロリズマブ、ニボルマブ、アテゾリズマブなどの免疫チェックポイント阻害剤は、特にPD-L1発現腫瘍に対する初回治療および維持療法において新しい時代の到来を告げています。これらの治療薬は、がん細胞を認識して破壊する免疫系の能力を強化し、単剤療法または化学療法と免疫療法の併用療法として、NSCLC治療の主流となっています。早期ステージの患者を対象とした新たな適応症が出現し続けており、ネオアジュバントまたはアジュバント免疫療法の臨床試験は有望な結果を出しています。バイオテクノロジーのパイプラインでは、免疫の逃避や抵抗性のメカニズムを克服するために、TIGIT、LAG-3、STINGアゴニストなどの新規免疫調節剤の研究も進められています。

市場力学において診断薬、スクリーニングプログラム、地域格差はどのような役割を果たすか？

早期診断は、肺がん管理における最大のアンメットニーズの一つです。ほとんどの地域では、肺がんの大部分は治癒治療がほとんど不可能なステージIIIまたはIVで発見されています。低線量CT検診プログラムが効果的に実施されれば、早期発見により死亡率が低下することが示されています。しかし、このようなプログラムの導入は、インフラの制約、コストの障壁、患者の意識のギャップにより、世界的に不均一なままです。サービスが行き届いていない地域でのAI支援放射線診断と移動式診断装置の統合は、早期発見率を向上させる上で有望です。

コンパニオン診断は、特に標的療法と免疫療法の適格性において、治療選択の要となりつつあります。単一の生検サンプルから複数の変異を解析できるNGSプラットフォームは、治療決定の指針としてますます使用されるようになっています。しかし、検査の利用可能性における地域格差は、低資源環境における個別化医療へのアクセスを制限し続けています。高所得国では、リアルタイムの分子腫瘍検査とアルゴリズム主導の治療決定が動向となっているが、低所得地域では、制度的課題が依然としてバイオマーカー主導のアプローチを制限しています。

肺がん市場の長期的成長と治療拡大の原動力は？

肺がん治療市場の成長は、技術革新のパイプライン、患者層の拡大、規制の加速、世界のがん罹患率の上昇など、複数の力によって牽引されています。主要な推進力は、次世代キナーゼ阻害剤、二重特異性抗体、ADC（抗体薬物複合体）の新規承認が着実に進んでいることであり、これらによって治療手段が拡大しています。製薬会社は、ニッチな亜集団を捕捉し、実際の価値を直接比較試験で実証するために、バイオマーカー調査と試験ネットワークに多額の投資を行っています。

政策や償還の環境は、特にQOLの向上や生存期間の大幅な延長をもたらすような、インパクトの大きい治療法を支持する方向に進化しています。条件付き承認、ファスト・トラック指定、複数国での臨床試験により、特に高負担地域における迅速な市場参入が促進されています。一方、患者擁護団体や臨床ネットワークは、公平なアクセス、治療後のサバイバーシップケア、薬剤の購入可能性などに対する要求を高めており、臨床的有効性だけでなく、治療提供の範囲を広げています。

AI主導の創薬、ctDNAベースのモニタリング、腫瘍オーガノイドなどの新たな技術は、肺がんの治療と追跡方法をさらに変革すると予想されます。この病気が一枚岩の課題から高度に細分化された治療ランドスケープへと移行するにつれ、肺がん治療市場は持続的なイノベーション、世界の拡大、診断、治療、デジタルケアプラットフォーム間の分野横断的な統合が進む態勢を整えています。

セグメント

がんタイプ（NSCLCがんタイプ、SCLCがんタイプ）、治療タイプ（手術、放射線療法、標的療法、免疫療法、化学療法、その他の治療タイプ）、エンドユーザー（病院エンドユーザー、がん・放射線治療センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例（注目の34社）

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Merck KGaA
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company
• Teva Pharmaceutical Industries Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Lung Cancer Treatment Market to Reach US$79.1 Billion by 2030

The global market for Lung Cancer Treatment estimated at US$50.9 Billion in the year 2024, is expected to reach US$79.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. NSCLC Cancer Treatment, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$46.2 Billion by the end of the analysis period. Growth in the SCLC Cancer Treatment segment is estimated at 9.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.9 Billion While China is Forecast to Grow at 11.7% CAGR

The Lung Cancer Treatment market in the U.S. is estimated at US$13.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.6 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Lung Cancer Treatment Market - Key Trends & Drivers Summarized

Why Does Lung Cancer Remain a Central Focus in Global Oncology Innovation?

Lung cancer continues to represent one of the most formidable challenges in global oncology, accounting for the highest number of cancer-related deaths worldwide. Divided primarily into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), the disease is often diagnosed at advanced stages, leading to poor prognosis and high treatment urgency. The historical reliance on chemotherapy and radiation therapy is now giving way to more personalized, targeted, and immune-based approaches that are transforming treatment paradigms. Innovations in molecular diagnostics, biomarker discovery, and precision therapeutics are allowing clinicians to tailor therapies based on genetic mutations, histological subtypes, and immune profiles.

The urgency to improve survival outcomes has led to the accelerated adoption of immunotherapies, targeted kinase inhibitors, and combination regimens that deliver incremental yet meaningful gains in progression-free and overall survival. Liquid biopsy tools, next-generation sequencing (NGS), and companion diagnostics are helping oncologists match patients to the right therapy with unprecedented precision. These developments, though complex and cost-intensive, are gradually reshaping lung cancer from a uniformly grim diagnosis to a series of stratified, biomarker-defined disease states with variable treatment pathways.

How Are Targeted Therapies and Immunotherapies Reshaping Clinical Practice?

One of the most transformative changes in lung cancer treatment has been the expansion of targeted therapies for patients with actionable mutations such as EGFR, ALK, ROS1, BRAF, and MET. These therapies, including osimertinib, crizotinib, and entrectinib, block abnormal signaling pathways that drive tumor growth. Their adoption has extended survival and improved quality of life for patients who would have otherwise undergone cytotoxic chemotherapy. Moreover, resistance mutations-such as T790M in EGFR-positive tumors-are now being addressed with second- and third-generation inhibitors, reflecting the growing complexity and personalization of treatment.

Immune checkpoint inhibitors such as pembrolizumab, nivolumab, and atezolizumab have ushered in a new era in first-line and maintenance therapy, particularly for PD-L1 expressing tumors. These agents enhance the immune system's ability to recognize and destroy cancer cells, and have become a mainstay in NSCLC treatment, either as monotherapy or in chemo-immunotherapy combinations. New indications continue to emerge for earlier-stage patients, and neoadjuvant or adjuvant immunotherapy trials are producing promising results. Biotech pipelines are also exploring novel immunomodulators such as TIGIT, LAG-3, and STING agonists to overcome immune escape and resistance mechanisms.

What Role Do Diagnostics, Screening Programs, and Regional Disparities Play in Market Dynamics?

Early diagnosis remains one of the greatest unmet needs in lung cancer management. In most regions, the majority of lung cancer cases are still detected at stage III or IV, when curative treatment is rarely possible. Low-dose CT screening programs, when implemented effectively, have been shown to reduce mortality through earlier detection. However, adoption of such programs remains uneven globally due to infrastructure constraints, cost barriers, and patient awareness gaps. The integration of AI-assisted radiology and mobile diagnostic units in underserved areas offers promise in improving early detection rates.

Companion diagnostics are becoming a linchpin in treatment selection, especially for targeted therapies and immunotherapy eligibility. NGS platforms capable of analyzing multiple mutations from a single biopsy sample are increasingly used to guide therapy decisions. Regional disparities in testing availability, however, continue to limit access to personalized care in low-resource settings. In high-income countries, the trend is toward real-time molecular tumor boards and algorithm-driven treatment decisions, while in lower-income regions, systemic challenges still restrict the reach of biomarker-driven approaches.

What Is Driving Long-Term Growth and Therapeutic Expansion in the Lung Cancer Market?

The growth in the lung cancer treatment market is driven by multiple forces including innovation pipelines, expanding patient pools, regulatory acceleration, and rising global cancer incidence. A key driver is the steady stream of new approvals for next-generation kinase inhibitors, bispecific antibodies, and ADCs (antibody-drug conjugates), which are expanding the therapeutic arsenal. Pharma companies are investing heavily in biomarker research and trial networks to capture niche subpopulations and demonstrate real-world value in head-to-head comparative studies.

Policy and reimbursement environments are evolving in favor of high-impact therapies, particularly those that offer measurable quality-of-life gains or extend survival significantly. Conditional approvals, fast-track designations, and multi-country trials are facilitating quicker market access, especially in high-burden regions. Meanwhile, patient advocacy groups and clinical networks are increasing demand for equitable access, post-treatment survivorship care, and drug affordability-broadening the scope of treatment delivery beyond just clinical efficacy.

Emerging technologies such as AI-driven drug discovery, ctDNA-based monitoring, and tumor organoids are expected to further revolutionize how lung cancer is treated and tracked. As the disease transitions from a monolithic challenge to a highly segmented therapeutic landscape, the market for lung cancer treatments is poised for sustained innovation, global expansion, and cross-disciplinary integration between diagnostics, therapeutics, and digital care platforms.

SCOPE OF STUDY:

The report analyzes the Lung Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (NSCLC Cancer Type, SCLC Cancer Type); Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy, Other Treatment Types); End-User (Hospitals End-User, Cancer & Radiation Therapy Centers End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Merck KGaA
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Lung Cancer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of NSCLC and SCLC Drives Demand for Targeted Lung Cancer Therapies
  • Expansion of Immuno-Oncology Research Throws the Spotlight on Checkpoint Inhibitors and CAR-T
  • Rapid Advancements in Liquid Biopsy and Genomic Profiling Propel Precision Treatment Strategies
  • FDA Approvals of Targeted Therapies Strengthen Business Case for Personalized Oncology
  • Integration of AI in Oncology Diagnostics Enhances Early Detection and Drug Matching Efficiency
  • Increased Investment in Biologics and Monoclonal Antibodies Accelerates Treatment Pipeline Growth
  • Surge in Companion Diagnostics Development Expands Addressable Patient Population for Targeted Drugs
  • Shift Toward Combination Therapy Protocols Spurs Demand for Multimodal Lung Cancer Regimens
  • Growth in Biomarker-Based Clinical Trial Design Enhances Efficiency in Drug Approval Pathways
  • Improved Access to Molecular Testing in Emerging Markets Supports Broader Therapy Adoption
  • Development of EGFR, ALK, and KRAS Inhibitors Sustains Growth in Precision Drug Categories
  • Rise in Smoking Cessation Programs and Awareness Campaigns Drives Preventive Screening Uptake
  • Expansion of Outpatient Oncology Care Models Enhances Access to Maintenance Therapies
  • Cost Containment Policies and Tiered Pricing Accelerate Penetration of Novel Drugs in LMICs
  • Pharma Collaborations and Licensing Agreements Strengthen Global Launch Strategies
  • Growth in Inhaled Chemotherapy Delivery Systems Enhances Drug Localization and Reduces Side Effects
  • Real-World Data Integration Strengthens Value-Based Pricing Models in Oncology Treatment
  • Focus on Minimally Invasive Surgical and Radiotherapy Techniques Expands Multidisciplinary Treatment
  • Reimbursement Policy Reforms in High-Incidence Markets Boost Therapy Accessibility
  • Immunotherapy Resistance and Mutation Complexity Create Need for Second-Line Drug Innovation
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Lung Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Lung Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for NSCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for NSCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for NSCLC Cancer Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for SCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for SCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for SCLC Cancer Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cancer & Radiation Therapy Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cancer & Radiation Therapy Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Cancer & Radiation Therapy Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• JAPAN
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• CHINA
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• EUROPE
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Lung Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• FRANCE
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• GERMANY
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Lung Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• INDIA
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Lung Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Lung Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030
• AFRICA
  • Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

IV. COMPETITION